Search results
We'd love to hear from you,please visit our contact page. We are seeking out-licensing and export opportunities for our expanding UK-licensed portfolio. We have a range of generic medicines available in novel doses and formulations in a diverse range of therapy areas.
Dec 15, 2023 · At Colonis, we harness our out-licensing partnerships to deliver high-quality, value-added medicines to new markets, certifying future growth and ensuring continued progress. The benefits of out-licensing. Out-licensing offers a host of advantages for pharmaceutical companies seeking a streamlined path to commercialisation in a new market.
People also ask
How does out-licensing work in pharmaceuticals?
What makes Colonis unique?
How does Colonis make a bigger impact?
Why is out-licensing a patent a good idea?
Dec 20, 2023 · Understanding in-licensing medicines. In-licensing involves acquiring the rights to license a pharmaceutical product that has been developed by another company. Unlike out-licensing, where licenses are granted to external partners, in-licensing focuses on bringing external assets into your portfolio. This approach offers several distinct ...
We’re an innovative company with great ambition to develop value-added medicines and treatment options that empower patients’ lives. We’re experts in repurposing medicines, transforming existing molecules, and optimising existing therapies. Our dedicated team carries out meticulous research and data analysis to identify and understand ...
Aug 7, 2023 · August 7, 2023. Dealmaking in the pharmaceutical and biotech industries plays a pivotal role in fostering growth and innovation. Partnering and out-licensing, also referred to as outlicensing, is an inorganic growth strategy, and often a key value-inflectional element for emerging pharma and biotech companies and their investors.
Out-licensing allows companies to extend their market presence by granting external partners the rights to manufacture and distribute their products. On the other hand, in-licensing provides companies with opportunities to diversify their product portfolios by acquiring external products or technologies. By understanding the difference between ...
What sets Colonis apart is our expertise to successfully navigate and commercialise a product beyond regulatory approvals. Each in-licensed product requires a tailored market access strategy that involves adaptable commercial expertise.
